Diabetes therapy to cost 80% less
Advertisement
A new drug based on the recently discovered molecule teneligliptin in the gliptin family is expected to bring down the cost of anti-diabetes therapy by 80%. This is likely to disrupt the existing medicine situation for treating diabetes, where the coat of a day’s therapy for diabetes is as high as Rs 1370 per day.
With the launch of this new molecule the gliptin family has witnessed erosion; with 15 companies offering the new molecule based drugs the cost has now come down from Rs 44 per day to Rs 9 per day.
The gliptin family occupies 20% share of the anti diabetes market, and the new teneligliptin is the fastest selling drug in the Rs 1430 crore gliptin family.
Taking the lead in the gliptin family is the new teneligliptin drug priced at Rs 20 launched by Glenmark in June last year. With the launch of Zita Plus and Ziten (teneligliptin brands) by Glenmark, there was a series of launch by other players creating lot of action in the Rs 6000 crore oral diabetic market, led by the launch of the new molecule.
With the launch of this new molecule the gliptin family has witnessed erosion; with 15 companies offering the new molecule based drugs the cost has now come down from Rs 44 per day to Rs 9 per day.
The gliptin family occupies 20% share of the anti diabetes market, and the new teneligliptin is the fastest selling drug in the Rs 1430 crore gliptin family.
Taking the lead in the gliptin family is the new teneligliptin drug priced at Rs 20 launched by Glenmark in June last year. With the launch of Zita Plus and Ziten (teneligliptin brands) by Glenmark, there was a series of launch by other players creating lot of action in the Rs 6000 crore oral diabetic market, led by the launch of the new molecule.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.